Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases

Biochemical Pharmacology

Volumn 85, Issue 7, 2013, Pages 865-872

  Saito, Hideyuki ^a,b  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Acute kidney injury; Chronic kidney disease; Nrf2; Renal tubules; Uremic toxins

Indexed keywords

AST 120; BARDOXOLONE METHYL; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; CISPLATIN; CURCUMIN; FUMARIC ACID DIMETHYL ESTER; INDICAN; KELCH LIKE ECH ASSOCIATED PROTEIN 1; QUERCETIN; REACTIVE OXYGEN METABOLITE; RESVERATROL; SULFORAPHANE; SUPEROXIDE; TRANSCRIPTION FACTOR NRF2;

ACUTE KIDNEY FAILURE; AGING; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CARDIORENAL SYNDROME; CHEMICAL MODIFICATION; CHRONIC KIDNEY DISEASE; DEFENSE MECHANISM; DIABETIC NEPHROPATHY; HUMAN; HYPERGLYCEMIA; INTRACELLULAR SIGNALING; KIDNEY CELL; KIDNEY DISEASE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN FUNCTION; RENAL PROTECTION; REVIEW; UBIQUITINATION;

EID: 84874666255     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2013.01.006     Document Type: Note

References (69)

1. E.L. Schiffrin, M.L. Lipman, and J.F. Mann Chronic kidney disease: effects on the cardiovascular system Circulation 116 2007 85 97 (Pubitemid 47016250)
2. M.G. Shlipak, P.A. Heidenreich, H. Noguchi, G.M. Chertow, W.S. Browner, and M.B. McClellan Association of renal insufficiency with treatment and outcomes after myocardial infarction in elderly patients Ann Intern Med 137 2002 555 562
3. Z.A. Massy, P. Stenvinkel, and T.B. Drueke The role of oxidative stress in chronic kidney disease Semin Dial 22 2009 405 408
4. E.O. Gosmanova, and N.A. Le Cardiovascular complications in CKD patients: role of oxidative stress Cardiol Res Pract 2011 Article ID 156326
5. L. Del Vecchio, F. Locatelli, and M. Carini What we know about oxidative stress in patients with chronic kidney disease on dialysis-clinical effects, potential treatment, and prevention Semin Dial 24 2011 56 64
6. P.S. de Souza, L.G. da Rocha, C.B. Tromm, D.L. Scheffer, E.G. Victor, and P.C. da Silveira Therapeutic action of physical exercise on markers of oxidative stress induced by chronic kidney disease Life Sci 91 2012 132 136
7. I.M. Copple The Keap1-Nrf2 cell defense pathway-a promising therapeutic target Adv Pharmacol 63 2012 43 79
8. K.N. Lewis, J. Mele, J.D. Hayes, and R. Buffenstein Nrf2, a guardian of healthspan and gatekeeper of species longevity Integr Comp Biol 50 2010 829 843
9. S. Magesh, Y. Chen, and L. Hu Small molecule modulators of Keap1-Nrf2-ARE pathway as potential preventive and therapeutic agents Med Res Rev 32 2012 687 726
10. J.W. Kaspar, S.K. Niture, and A.K. Jaiswal Nrf2:INrf2 (Keap1) signaling in oxidative stress Free Radic Biol Med 47 2009 1304 1309
11. K.A. Jung, and M.K. Kwak The Nrf2 system as a potential target for the development of indirect antioxidants Molecules 15 2010 7266 7291
12. J. Kim, Y.M. Seok, K.J. Jung, and K.M. Park Reactive oxygen species/oxidative stress contributes to progression of kidney fibrosis following transient ischemic injury in mice Am J Physiol Renal Physiol 297 2009 F461 F470
13. Q.Q. Wu, Y. Wang, M. Senitko, C. Meyer, W.C. Wigley, and D.A. Ferguson Bardoxolone methyl (BARD) ameliorates ischemic AKI and increases expression of protective genes Nrf2, PPARγ, and HO-1 Am J Physiol Renal Physiol 300 2011 F1180 F1192
14. A. Kuchta, A. Pacanis, B. Kortas-Stempak, A. Cwiklińska, M. Ziȩtkiewicz, and M. Renke Estimation of oxidative stress markers in chronic kidney disease Kidney Blood Press Res 34 2011 12 19
15. D.M. Small, J.S. Coombes, N. Bennett, D.W. Johnson, and G.C. Gobe Oxidative stress, anti-oxidant therapies and chronic kidney disease Nephrology (Carlton) 17 2012 311 321
16. L.A. Sena, and N.S. Chandel Physiological roles of mitochondrial reactive oxygen species Mol Cell 48 2012 158 167
17. A.A. Alfadda, and R.M. Sallam Reactive oxygen species in health and disease J Biomed Biotechnol 2012 2012 936486
18. S.N. Heyman, S. Rosen, and C. Rosenberger A role for oxidative stress Contrib Nephrol 174 2011 138 148
19. R.I. van Haaften, G.R. Haenen, C.T. Evelo, and A. Bast Effect of vitamin E on glutathione-dependent enzymes Drug Metab Rev 35 2003 215 253 (Pubitemid 37048296)
20. A. Giudice, C. Arra, and M.C. Turco Review of molecular mechanisms involved in the activation of the Nrf2-ARE signaling pathway by chemopreventive agents Methods Mol Biol 647 2010 37 74
21. K. Itoh, J. Mimura, and M. Yamamoto Discovery of the negative regulator of Nrf2, Keap1: a historical overview Antioxid Redox Signal 13 2010 1665 1678
22. H.J. Kim, and N.D. Vaziri Contribution of impaired Nrf2-Keap1 pathway to oxidative stress and inflammation in chronic renal failure Am J Physiol Renal Physiol 298 2010 F662 F671
23. L.M. Pedruzzi, M.B. Stockler-Pinto, M. Leite Jr., and D. Mafra Nrf2-keap1 system versus NF-κB: The good and the evil in chronic kidney disease Biochimie 94 2012 2461 2466
24. K. Dobashi, B. Ghosh, J.K. Orak, I. Singh, and A.K. Singh Kidney ischemia-reperfusion: modulation of antioxidant defenses Mol Cell Biochem 205 2000 1 11 (Pubitemid 30216783)
25. N. Nitescu, S.E. Ricksten, N. Marcussen, B. Haraldsson, U. Nilsson, and S. Basu N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion Nephrol Dial Transplant 21 2006 1240 1247
26. H.Y. Yoon, N.I. Kang, H.K. Lee, K.Y. Jang, J.W. Park, and B.H. Park Sulforaphane protects kidneys against ischemia-reperfusion injury through induction of the Nrf2-dependent phase 2 enzyme Biochem Pharmacol 75 2008 2214 2223
27. P. Brunet, B. Gondouin, A. Duval-Sabatier, L. Dou, C. Cerini, and F. Dignat-George Does uremia cause vascular dysfunction Kidney Blood Press Res 3 2011 284 290
28. L. Dou, N. Jourde-Chiche, V. Faure, C. Cerini, Y. Berland, and F. Dignat-George The uremic solute indoxyl sulfate induces oxidative stress in endothelial cells J Thromb Haemost 5 2007 1302 1308 (Pubitemid 46902134)
29. M. Yu, Y.J. Kim, and D.H. Kang Indoxyl sulfate-induced endothelial dysfunction in patients with chronic kidney disease via an induction of oxidative stress Clin J Am Soc Nephrol 6 2011 30 39
30. Y. Adelibieke, H. Shimizu, G. Muteliefu, D. Bolati, and T. Niwa Indoxyl sulfate induces endothelial cell senescence by increasing reactive oxygen species production and p53 activity J Ren Nutr 22 2012 86 89
31. G. Muteliefu, A. Enomoto, P. Jiang, M. Takahashi, and T. Niwa Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells Nephrol Dial Transplant 24 2009 2051 2058
32. R. Vanholder, N. Meert, E. Schepers, G. Glorieux, A. Argiles, and P. Brunet European Uremic Toxin Work Group (EUTox) review on uraemic solutes II-variability in reported concentrations: causes and consequences Nephrol Dial Transplant 22 2007 3115 3121
33. S.T. Huang, K.H. Shu, C.H. Cheng, M.J. Wu, T.M. Yu, and Y.W. Chuang Serum total p-cresol and indoxyl sulfate correlated with stage of chronic kidney disease in renal transplant recipients Transplant Proc 44 2012 621 624
34. B.K. Meijers, H. De Loor, B. Bammens, K. Verbeke, Y. Vanrenterghem, and P. Evenepoel p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients Clin J Am Soc Nephrol 4 2009 1932 1938
35. I.W. Wu, K.H. Hsu, C.C. Lee, C.Y. Sun, H.J. Hsu, and C.J. Tsai p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease Nephrol Dial Transplant 26 2011 938 947
36. T. Deguchi, H. Kusuhara, A. Takadate, H. Endou, M. Otagiri, and Y. Sugiyama Characterization of uremic toxin transport by organic anion transporters in the kidney Kidney Int 65 2004 162 174 (Pubitemid 38037501)
37. Y. Miyamoto, H. Watanabe, T. Noguchi, S. Kotani, M. Nakajima, and D. Kadowaki Organic anion transporters play an important role in the uptake of p-cresyl sulfate, a uremic toxin, in the kidney Nephrol Dial Transplant 26 2011 2498 2502
38. A.K. Gelasco, and J.R. Raymond Indoxyl sulfate induces complex redox alterations in mesangial cells Am J Physiol Renal Physiol 290 2006 F1551 F1558
39. K. Taki, Y. Tsuruta, and T. Niwa Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients Am J Nephrol 27 2007 30 35 (Pubitemid 46364538)
40. H. Shimizu, D. Bolati, Y. Higashiyama, F. Nishijima, K. Shimizu, and T. Niwa Indoxyl sulfate upregulates renal expression of MCP-1 via production of ROS and activation of NF-κB, p53, ERK, and JNK in proximal tubular cells Life Sci 90 2012 525 530
41. T. Niwa Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120 Ther Apher Dial 15 2011 120 124
42. G. Schulman A nexus of progression of chronic kidney disease: tryptophan, profibrotic cytokines, and charcoal J Ren Nutr 22 2012 107 113
43. H. Fujii, K. Nakai, and M. Fukagawa Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease Ther Apher Dial 15 2011 125 128
44. D. Bolati, H. Shimizu, and T. Niwa AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats J Ren Nutr 22 2012 176 180
45. T. Niwa, M. Ise, and T. Miyazaki Progression of glomerular sclerosis in experimental uremic rats by administration of indole, a precursor of indoxyl sulfate Am J Nephrol 14 1994 207 212 (Pubitemid 24257961)
46. H. Saito Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications Pharmacol Ther 125 2010 79 91
47. T. Matsuzaki, H. Watanabe, K. Yoshitome, T. Morisaki, A. Hamada, and H. Nonoguchi Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure Kidney Int 71 2007 539 547 (Pubitemid 46398686)
48. S. Owada, S. Goto, K. Bannai, H. Hayashi, F. Nishijima, and T. Niwa Indoxyl sulfate reduces superoxide scavenging activity in the kidneys of normal and uremic rats Am J Nephrol 28 2008 446 454 (Pubitemid 351501611)
49. J. Rojas-Rivera, A. Ortiz, and J. Egido Antioxidants in kidney diseases: The impact of bardoxolone methyl Int J Nephrol 2012 Article ID 321714
50. H. Shibahara, and N. Shibahara Cardiorenal protective effect of the oral uremic toxin absorbent AST-120 in chronic heart disease patients with moderate CKD J Nephrol 23 2010 535 540
51. M. Boaz, S. Smetana, T. Weinstein, Z. Matas, U. Gafter, and A. Iaina Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial Lancet 356 2000 1213 1218
52. M. Tepel, M. van der Giet, M. Statz, J. Jankowski, and W. Zidek The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial Circulation 107 2003 992 995 (Pubitemid 36258722)
53. K. Nitta Clinical assessment and management of dyslipidemia in patients with chronic kidney disease Clin Exp Nephrol 16 2012 522 529
54. S.B. Kim, R.K. Pandita, U. Eskiocak, P. Ly, A. Kaisani, and R. Kumar Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation Proc Natl Acad Sci USA 109 2012 E2949 E2955
55. D.S. Hong, R. Kurzrock, J.G. Supko, X. He, A. Naing, and J. Wheler A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas Clin Cancer Res 18 2012 3396 3406
56. P.E. Pergola, M. Krauth, J.W. Huff, D.A. Ferguson, S. Ruiz, and C.J. Meyer Effect of bardoxolone methyl on kidney function in patients with T2D and Stage 3b-4 CKD Am J Nephrol 33 2011 469 476
57. P.E. Pergola, P. Raskin, R.D. Toto, C.J. Meyer, J.W. Huff, and E.B. Grossman Bardoxolone methyl and kidney function in CKD with type 2 diabetes N Engl J Med 365 2011 327 336
58. S.A. Reisman, G.M. Chertow, S. Hebbar, N.D. Vaziri, K.W. Ward, and C.J. Meyer Bardoxolone methyl decreases megalin and activates Nrf2 in the kidney J Am Soc Nephrol 23 2012 1663 1673
59. E. Tapia, V. Soto, K.M. Ortiz-Vega, G. Zarco-Márquez, E. Molina-Jijón, and M. Cristóbal-García Curcumin induces Nrf2 nuclear translocation and prevents glomerular hypertension, hyperfiltration, oxidant stress, and the decrease in antioxidant enzymes in 5/6 nephrectomized rats Oxid Med Cell Longev 2012 2012 269039 10.1155/2012/269039
60. M.H. Hanigan, and P. Devarajan Cisplatin nephrotoxicity: molecular mechanisms Cancer Ther 1 2003 47 61
61. E.B. Behling, M.C. Sendão, H.D. Francescato, L.M. Antunes, R.S. Costa, and L. Bianchi Mde Comparative study of multiple dosage of quercetin against cisplatin-induced nephrotoxicity and oxidative stress in rat kidneys Pharmacol Rep 58 2006 526 532 (Pubitemid 44383278)
62. C.E. Guerrero-Beltrán, M. Calderón-Oliver, E. Tapia, O.N. Medina-Campos, D.J. Sánchez-González, and C.M. Martínez-Martínez Sulforaphane protects against cisplatin-induced nephrotoxicity Toxicol Lett 192 2010 278 285
63. T. Morisaki, T. Matsuzaki, K. Yokoo, M. Kusumoto, K. Iwata, and A. Hamada Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats Pharm Res 25 2008 2526 2533
64. M. Kusumoto, H. Kamobayashi, D. Sato, M. Komori, M. Yoshimura, and A. Hamada Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats Clin Exp Nephrol 15 2011 820 830
65. P. Palsamy, and S. Subramanian Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling Biochim Biophys Acta 1812 2011 719 731
66. R. Gold, L. Kappos, D.L. Arnold, A. Bar-Or, G. Giovannoni, and K. Selmaj Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis N Engl J Med 367 2012 1098 1107
67. B.M. Hybertson, B. Gao, S.K. Bose, and J.M. McCord Oxidative stress in health and disease: The therapeutic potential of Nrf2 activation Mol Aspects Med 32 2011 234 246
68. Z.F. Luo, W. Qi, B. Feng, J. Mu, W. Zeng, and Y.H. Guo Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome Life Sci 88 2011 512 520
69. W. Cui, Y. Bai, B. Li, X. Miao, Q. Chen, and W. Sun Potential role for Nrf2 activation in the therapeutic effect of MG132 on diabetic nephropathy in OVE26 diabetic mice Am J Physiol Endocrinol Metab 304 November 2013 E87 E99